一纸人事公告,击穿扬子江药业“不搞兼并” 的家训,创新疫苗赛道的生死棋局,骤然落子。 近日,江苏瑞科生物技术股份有限公司(02179.HK)发布重磅人事公告,创始人刘勇博士正式辞去董事长及提名委员会主席职务。公告明确,刘勇辞任的核心原因是“进一步提升公司治理水平”及“计划倾注更多时间于其他工作”,辞任后仍将继续担任公司执行董事及总经理,全面主持生产经营管理工作。 与刘勇辞任同步,瑞科生物董事会...
Source Link一纸人事公告,击穿扬子江药业“不搞兼并” 的家训,创新疫苗赛道的生死棋局,骤然落子。 近日,江苏瑞科生物技术股份有限公司(02179.HK)发布重磅人事公告,创始人刘勇博士正式辞去董事长及提名委员会主席职务。公告明确,刘勇辞任的核心原因是“进一步提升公司治理水平”及“计划倾注更多时间于其他工作”,辞任后仍将继续担任公司执行董事及总经理,全面主持生产经营管理工作。 与刘勇辞任同步,瑞科生物董事会...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.